# OnCo record lag3-blockade (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/lag3-blockade/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "lag3-blockade" ;
  schema:name "LAG-3 blockade"@en ;
  schema:description "Antibodies against LAG-3, another brake on tired T cells; relatlimab plus nivolumab became the first approved LAG-3 combination for melanoma in 2022."@en ;
  schema:url <https://onco.cc/technologies/lag3-blockade/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/LAG3> ;
  schema:citation <https://en.wikipedia.org/wiki/LAG3> ;
  onco:status "approved" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:targets <https://onco.cc/targets/lag3/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> .